Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of NNI-362 in Healthy Aged Volunteers
NCT04074837Phase 1Completed
- Sponsor
- Neuronascent
- Start
- Aug 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nni-362 in Alzheimer's disease (AD) (6 arms), sponsored by Neuronascent. Primary endpoint: Number of treatment related adverse events. Started Aug 2019; status: completed.
02
Drugs
nni-362
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04074837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04074837.